Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Revelation Biosciences Inc
REVB
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$3.63
-0.12
-3.2%
Últ. Act.: Oct 21, 4:54 PM
$3.60
-0.15
-4%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
División de acciones:
Se espera que Revelation Biosciences Inc se divida Tuesday, October 20, 2026 con una proporción de 1:7
Revelation Biosciences Financials
Revelation Biosciences (REVB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(0.88) by 1.14 percent. This is a 87.59 percent increase over losses of $(7.01) per share
Benzinga Newsdesk
PRO
Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the analyst consensus estimate of $(1.55) by 74.84 percent. This is a 89.31 percent increase over losses of $(25.34) per
Benzinga Newsdesk
PRO
Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.96) by 71.88 percent. This is a 97.24 percent increase over losses of $(59.76) per
Benzinga Newsdesk
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED)
US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP exceeds estimates.
Vishaal Sanjay
PRO
Revelation Biosciences Q3 EPS $(1.77) Misses $(1.33) Estimate
Benzinga Newsdesk
PRO
Revelation Biosciences Q2 EPS $(7.01) Misses $(1.49) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(7.01) per share which missed the analyst consensus estimate of $(1.49) by 372.05 percent. This is a 97.15 percent increase over losses of $(246.24) per
Benzinga Newsdesk
